MEDICINAL CHEMISTRY - 2020/1
Module code: CHE3062
In light of the Covid-19 pandemic, and in a departure from previous academic years and previously published information, the University has had to change the delivery (and in some cases the content) of its programmes, together with certain University services and facilities for the academic year 2020/21.
These changes include the implementation of a hybrid teaching approach during 2020/21. Detailed information on all changes is available at: https://www.surrey.ac.uk/coronavirus/course-changes. This webpage sets out information relating to general University changes, and will also direct you to consider additional specific information relating to your chosen programme.
Prior to registering online, you must read this general information and all relevant additional programme specific information. By completing online registration, you acknowledge that you have read such content, and accept all such changes.
The module provides well-rounded knowledge and understanding of medicinal chemistry. Through its employment of example drug discovery projects from the research areas of viruses, antibiotics, diabetes, adrenergic receptors, cancer, including nuclear medicine, nanotherapeutics and inorganic medicinal chemistry, it provides students with an appreciation of design and discovery strategies which should allow them to critically evaluate new medicinal chemistry projects as well as suggest new research directions and ideas for improvements.
WHELLIGAN Daniel (Chemistry)
Number of Credits: 15
ECTS Credits: 7.5
Framework: FHEQ Level 6
Module cap (Maximum number of students): N/A
Prerequisites / Co-requisites
Indicative module content:
Target validation using genetic engineering molecular biology tools.
An introduction to X-ray crystallography and structure based design.
Advanced binding interactions: ΔG, binding role of functional groups and amino acids, the hydrophobic effect.
Viruses and antiviral drugs. Vaccines and antiviral drugs. DNA chain terminators. Enzymes: kinases, peptidases, reversible inhibitors.
Adrenergic receptors: GPCRs, agonists, antagonists, partial agonists, affinity, efficacy, potency. Associated drugs, their mechanisms of action and discovery.
Antibiotics, their discovery. Natural and semisynthetic β–lactams (penicillins and cephalosporins), their mechanism of action. Other antibiotics, the problem of drug resistance (MRSA etc).
Diabetes, mechanisms of action of insulin and drugs. Discovery of new therapeutics. Kinase-linked receptors, ligand gated ion-channel receptors, signal transduction.
Cancer and chemotherapy. Nucleic acids as drug targets. The design of modern targeted therapeutics.
Metal ions and chelating agents in therapy. Ligand design, choice of metal ion and targeting strategies.
Radioisotopes for biological imaging and therapy. Ligand design and targeting strategies.
Radioisotope production, radioloabelling and radioimmunoassay
Process chemistry, scale-up.
The pharmaceutical industry. Generic drugs. Ethical aspects. Clinical trials. Patents
|Assessment type||Unit of assessment||Weighting|
|Examination||EXAMINATION 1.5 HR||80|
The assessment strategy is designed to provide students with the opportunity to demonstrate:
• the ability to research, understand and critically evaluate drug discovery programmes reported in the literature, against a target not met in lectures, by applying knowledge gained in the module;
Thus, the summative assessment for this module consists of:
• coursework incorporating a review of medicinal chemistry programmes on a given target
• examination (1.5 h)
Small problem-solving tasks are included in some lectures. During the task, the lecturer moves amongst the groups commenting and guiding the students’ starting points and answering strategies. Common difficulties are highlighted to the whole class and the final solution is given on the board/visualiser.
Feedback to the written review consists of annotations on the returned document and a breakdown of marks into specific headings along with written general feedback giving justifications for the marks and suggestions for improvement.
- • give students an advanced understanding of how therapeutics work and are designed, discovered and developed.
- • provide students with a conceptual understanding of drug discovery, for several disease classes, through medicinal chemistry examples
|001||Understand the targeting of biological pathways with drugs to treat several major disease classes||KC|
|002||Review and critically evaluate material describing the mode of action, discovery and development of known drugs||CPT|
|003||Apply medicinal chemistry methods for the determination of structure-activity relationships and improvement of drug pharmacodynamics and pharmacokinetics||KCP|
|004||Understand and critically evaluate late-stage and modern drug development strategies including process chemistry and the design of nanotherapeutics||KC|
|005||Conceptually rationalise the role of metal complexes in diagnostics and therapy and be able to solve problems related to their use||KCP|
C - Cognitive/analytical
K - Subject knowledge
T - Transferable skills
P - Professional/Practical skills
Overall student workload
Independent Study Hours: 119
Lecture Hours: 30
Tutorial Hours: 1
Methods of Teaching / Learning
The learning and teaching strategy is designed to:
• build on students’ knowledge of the drug discovery process, methods and characteristics of drugs by providing them with a fuller understanding of considerations during their design through the use of case studies in several specific areas.
• provide students with an ability to understand new drug discovery programmes, critically evaluate them and suggest future work or improvements.
The learning and teaching methods include:
• formal lectures which contain occasional group problem-solving tasks.
• coursework: a written critical review of published medicinal chemistry programmes for a given biomolecular target, not discussed in lectures, followed by suggested future directions.
• Revision tutorial (1 h)
• Written exam (1.5 h)
Indicated Lecture Hours (which may also include seminars, tutorials, workshops and other contact time) are approximate and may include in-class tests where one or more of these are an assessment on the module. In-class tests are scheduled/organised separately to taught content and will be published on to student personal timetables, where they apply to taken modules, as soon as they are finalised by central administration. This will usually be after the initial publication of the teaching timetable for the relevant semester.
Reading list for MEDICINAL CHEMISTRY : http://aspire.surrey.ac.uk/modules/che3062
Programmes this module appears in
|Chemistry with Forensic Investigation BSc (Hons)||2||Optional||A weighted aggregate mark of 40% is required to pass the module|
|Medicinal Chemistry BSc (Hons)||2||Compulsory||A weighted aggregate mark of 40% is required to pass the module|
|Chemistry BSc (Hons)||2||Optional||A weighted aggregate mark of 40% is required to pass the module|
Please note that the information detailed within this record is accurate at the time of publishing and may be subject to change. This record contains information for the most up to date version of the programme / module for the 2020/1 academic year.